News & Events

Rain Research Foundation Opioid Relapse Reduction Therapeutics Grant Announcement

February 15, 2018

Brain Research Foundation (BRF) is announcing a new grant initiative. BRF invites eligible Principal Investigators to submit a Letter of Intent (LOI) for the Opioid Relapse Reduction Therapeutics Grant by February 28, 2018. To be eligible, the PI must be a full-time tenure-track or tenured faculty at a U.S. institution, working in the area of study of opioid addiction. The goal of this program is to accelerate the development of new relapse reduction therapeutics.

Funding Opportunity Purpose:

The purpose of this request for proposals is to support the development of novel, translational research that will help accelerate the understanding of the mechanisms associated with opioid use disorders and addiction, targeted to medication development for new relapse reduction therapeutics.

The pre-clinical research areas of focus may include (but are not limited to):

  1. Neurobiology of relapse to drug taking
  2. Identifying new chemicals for high potential for relapse reduction
  3. Repurposing of FDA-approved therapies for relapse reduction
  4. Alternative therapies
  5. Vulnerability to relapse factors (e.g., genetics, epigenetics, environmental stresses)

Funding and award period: Based on the quality of applications, Brain Research Foundation will fund up to 2 grants on opioid relapse reduction research. Each total award is limited to $50,000 (direct costs) for a one year grant period. After the LOI is submitted and reviewed, if accepted, a notification with instructions to submit a full application will be sent in March 2018. If the application is approved, the faculty member will be notified in June 2018.

Please alert qualified faculty at your institution of this upcoming funding opportunity.

To download the LOI form, please click here to sign in or create account.

(Please note that to edit and save the LOI form, it must be opened in Adobe Acrobat).

For complete submission information and guidelines click here.

Email any inquiries to